ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $489,261 | -59.2% | 23,477 | -63.1% | 0.14% | -62.9% |
| Q1 2023 | $1,198,966 | +391.4% | 63,707 | +327.0% | 0.39% | +311.6% |
| Q3 2022 | $244,000 | +71.8% | 14,920 | +48.1% | 0.10% | +33.8% |
| Q2 2022 | $142,000 | -75.7% | 10,077 | -58.2% | 0.07% | -78.2% |
| Q1 2022 | $584,000 | +192.0% | 24,100 | +100.4% | 0.32% | +157.9% |
| Q3 2021 | $200,000 | -36.9% | 12,027 | -7.3% | 0.13% | -56.2% |
| Q2 2021 | $317,000 | -5.1% | 12,977 | +86.5% | 0.29% | -34.8% |
| Q2 2020 | $334,000 | -25.1% | 6,958 | -43.8% | 0.44% | +8.9% |
| Q3 2019 | $446,000 | +13.2% | 12,390 | -52.0% | 0.41% | +224.8% |
| Q2 2018 | $394,000 | -47.0% | 25,822 | +19.5% | 0.12% | -58.7% |
| Q1 2017 | $743,000 | +125.8% | 21,600 | +89.5% | 0.30% | +75.1% |
| Q4 2016 | $329,000 | – | 11,400 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 25,819,768 | $972,631,000 | 7.89% |
| SECTORAL ASSET MANAGEMENT INC | 822,392 | $30,980,000 | 3.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 240,773 | $9,068,000 | 3.53% |
| HARVEY CAPITAL MANAGEMENT INC | 230,700 | $8,690,000 | 3.51% |
| Palo Alto Investors LP | 1,641,030 | $61,818,000 | 2.60% |
| GARRISON BRADFORD & ASSOCIATES INC | 73,350 | $2,763,000 | 2.31% |
| EMORY UNIVERSITY | 52,977 | $1,996,000 | 1.58% |
| Sivik Global Healthcare LLC | 120,000 | $4,520,000 | 1.54% |
| Stanley-Laman Group, Ltd. | 143,876 | $5,420,000 | 1.45% |
| ACUTA CAPITAL PARTNERS, LLC | 170,000 | $6,404,000 | 1.15% |